Of the tracked stories, 1 of 2 also mention Bluejay Diagnostics, Inc., the most common co-covered peer. The clearest coverage concentration is health-it: 1 of 2 stories, with the rest divided among 1 other category. Source depth averages 2 original sources per story, versus 2.2 across the same-window beat baseline.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about MarketBeat.com
Of the tracked stories, 1 of 2 also mention Bluejay Diagnostics, Inc., the most common co-covered peer. The clearest coverage concentration is health-it: 1 of 2 stories, with the rest divided among 1 other category. Source depth averages 2 original sources per story, versus 2.2 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 5.4 for that window. We currently track 2 Healthcare stories that mention MarketBeat.com, published between August 12, 2026 and August 16, 2026.
Stories tracked
2
Sources per story
2
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 74 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering MarketBeat.com. Shared-story counts are live from our verified record — not editorial picks.
Lantern Pharma's quarterly EPS miss of $0.19 highlights the cash-intensive nature of AI-powered oncology drug discovery. The clinical-stage company has no product revenue, and its stock trades well below moving averages. Healthcare executives should monitor its platform and funding runway rather than quarterly losses.
This review offers healthcare strategists a snapshot of two small-cap suppliers: NexGel's insider-heavy ownership and stronger profitability versus Bluejay's institutionally backed diagnostic platform.
MarketBeat.com is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.